3,5-dihydroxy-4,4-dimethyl-2-(2-methylpropanoyl)-6-{[2,4,6-trihydroxy-3-(3-methylbut-2-en-1-yl)-5-(2-methylpropanoyl)phenyl]methyl}cyclohexa-2,5-dien-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,5-dihydroxy-4,4-dimethyl-2-(2-methylpropanoyl)-6-{[2,4,6-trihydroxy-3-(3-methylbut-2-en-1-yl)-5-(2-methylpropanoyl)phenyl]methyl}cyclohexa-2,5-dien-1-one
• 英文别名: uliginosin A
• 化学式: C₂₈H₃₆O₈
• 分子量: 500.589
• InChiKey: SBVAYWWFCDLDFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.15
• 重原子数：
  36.0
• 可旋转键数：
  8.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  152.36
• 氢给体数：
  5.0
• 氢受体数：
  8.0

文献信息

• US7854946B1
  申请人：——

  公开号：US7854946B1

  公开（公告）日：2010-12-21
• [EN] NEUROACTIVE PLANT EXTRACT FROM HYPERICUM POLYANTHEMUM<br/>[FR] EXTRAIT NEUROACTIF DE PLANTE OBTENU À PARTIR DE HYPERICUM POLYANTHEMUM
  申请人：UNIV ROUEN

  公开号：WO2010092162A1

  公开（公告）日：2010-08-19

  The present invention belongs to the field of plant extracts with activity on the central nervous system. Specifically, the plant extract of the present invention is an extract obtained from Hypericum polyanthemum and comprising the compound uliginosin B and/or compounds from the class of benzopyrans such as. The present invention also relates to a pharmaceutical composition comprising such an extract which has pharmacological action in psychiatric disorders, such as mood disorders, specifically, anti-depressant activity. Such as HP1 (6-isobutyryl-5,7-dimethoxy-2,2-dimethyl-benzopyran), HP2 (7-hydroxy-6-isobutyryl-5-methoxy-2,2-dimethyl-benzopyran) and HP3 (5-hydroxy-6-isobutyryl-7-methoxy-2,2-dimethyl-benzopyran)).
• [EN] COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES<br/>[FR] COMPOSITIONS ET PROCÉDÉS ASSOCIÉS À DES OXYDES DISSOUS
  申请人：NATURAL EXTRACTION SYS LLC

  公开号：WO2021042001A1

  公开（公告）日：2021-03-04

  Various aspects of this patent document relate to compositions that comprise an anion that is the conjugate base of a hydrophobic molecule that has a pKa, for example, of at least 7 and no greater than 12. These compositions display improved properties when formulated to interact with an organism because the anions carry negative charges that allows them to both dissolve in water-miscible liquids and maximize their surface area. Interaction with an organism results in at least partial conversion of the anion into the hydrophobic molecule after which the hydrophobic molecule partitions out of a water-miscible liquid and into the organism.
• [EN] METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES<br/>[FR] PROCÉDÉS LIÉS À DES AGENTS BIOACTIFS QUI CONVERTISSENT DES ANIONS EN MOLÉCULES
  申请人：NATURAL EXTRACTION SYS LLC

  公开号：WO2021158573A1

  公开（公告）日：2021-08-12

  Various aspects of this patent document relate to bioactive compositions comprising anions that are converted into hydrophobic bioactive molecules either ex vivo prior to administration to a subject or in situ subsequent to administration to a subject. Such compositions display improved bioavailability and pharmacokinetics relative to compositions that comprise the hydrophobic bioactive molecules instead of the anions.
• [EN] COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES<br/>[FR] COMPOSITIONS ASSOCIÉES À DES AGENTS BIOACTIFS QUI CONVERTISSENT DES ANIONS EN MOLÉCULES
  申请人：NATURAL EXTRACTION SYS LLC

  公开号：WO2021158575A1

  公开（公告）日：2021-08-12

  Various aspects of this patent document relate to bioactive compositions comprising anions that are converted into hydrophobic bioactive molecules either ex vivo prior to administration to a subject or in situ subsequent to administration to a subject. Such compositions display improved bioavailability and pharmacokinetics relative to compositions that comprise the hydrophobic bioactive molecules instead of the anions.